FDA Approves Amylyx Drug To Slow ALS Progression

  • The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc’s drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.
  • Amylyx’s case for approval was built on a recent analysis of clinical trial data that it said showed the drug slows progression of the disease and extends life expectancy by nearly 10 months.
  • Shares of the drugmaker were up nearly 7 percent in extended trading following the approval.
Click to read full article Go back home

Sign Up for Our Newsletter

Join our list!

Sign up here to get our daily newsletter with the top trending headlines.